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In the recent years, circulating microRNAs (miRNAs) have garnered a lot of attention and
interest in the field of disease biomarkers. With characteristics such as high stability, low
cost, possibility of repeated sampling and minimal invasiveness, circulating miRNAs are
ideal for development into diagnostic tests. There have been many studies reported on the
potential of circulating miRNAs as early detection, prognostic, and predictive biomarkers
in cancer. Here, we have reviewed the application of plasma and serum miRNAs as
biomarkers for cancer focusing on epithelial carcinomas [prostate, breast, lung, colorectal,
and gastric cancer (GC)] and hematological malignancies (leukemia and lymphoma). We
have also addressed the common challenges that need to be overcome to achieve a
successful bench to bedside transition.
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INTRODUCTION
Cancer accounts for the highest mortality in developed countries,
and second highest in developing countries, making it a world-
wide health problem (Ferlay et al., 2008; Siegel et al., 2012). One
method of disease management is the development of biomark-
ers, which could enhance early cancer detection, improve patient
stratification and therapy response prediction. This in turn would
result in a more favorable disease outcome. Blood-based protein
biomarkers, such as carcinoembryonic antigen (CEA), carbo-
hydrate antigen (CA), or prostate specific antigen (PSA), have
gained a lot of recognition. Nevertheless, they suffer from low sen-
sitivity, especially with respect to their use in screening for early
stages or inability to distinguish aggressive from indolent tumors
(Lumachi et al., 2000; Hanash et al., 2011). This has prompted the
investigation for novel and more sensitive biomarkers, which can
supplement or complement existing detection methods and aid
in disease monitoring.
Since their discovery, microRNAs (miRNAs) have proven to be
an essential and indispensable layer in gene regulation, mainly,
post-transcriptional regulation. Involved in many physiological
processes and also found to be deregulated in many disease
mechanisms, miRNAs have also gained importance as they carry
information about the patho-physiological state of a person, and
thus can serve as biomarkers. miRNAs present in the cell-free
body fluids such as plasma, serum, urine, saliva, etc., termed as
circulating miRNAs, have been exploited as biomarkers in many
diseases in the past five years. Placental miRNAs were the first
class of circulating miRNAs to be detected in maternal plasma
during pregnancy (Chim et al., 2008). Parallel to this discovery,
miRNAs were found to be elevated in the serum of lymphoma
patients compared to healthy individuals (Lawrie et al., 2008).
Since then circulating miRNAs have attracted a great deal of
attention as novel, minimally invasive biomarkers for various
diseases. Features such as ease of access and remarkable stabil-
ity increase their potential as disease biomarkers (Mitchell et al.,
2008; Turchinovich et al., 2011). Since they are bound to pro-
teins like argonaute (AGO) or high density lipoprotein, they
are highly resistant to RNase activity, unlike mRNAs measured
in gene signature markers (Turchinovich and Burwinkel, 2012).
Detection of miRNAs by quantitative polymerase chain reac-
tion (qPCR) has the advantages of being relatively inexpensive,
sensitive to even low amounts due to amplification of signal,
and robust. In these terms, they seem to have an edge over
protein markers, which currently represent the most common
circulating biomarker type. A further testament to their diverse
and dynamic uses in a clinical settings is the various reports
outlining use of circulating miRNAs as a diagnostic, prognos-
tic and predictive marker (Figure 1). The impact of circulating
miRNAs in the field of biomarkers has been unequivocal with
more than 250 studies probing their use in cancer diagnosis and
prognosis.
In this review, we have summarized the recent-findings in
cancer related circulating miRNAs and presented them also in a
tabular form, with a focus on epithelial cancers such as prostate
www.frontiersin.org June 2013 | Volume 4 | Article 116 | 1
Madhavan et al. Circulating microRNAs in cancer
FIGURE 1 | Representation of the diagnostic, prognostic, and predictive uses of circulating miRNAs as a biomarker using lung cancer as an example.
and gastric (Table 5) cancer, and also touched upon lymphomas
and leukemia (Table 6). We present a comprehensive summary
of circulating miRNAs present in plasma or serum which are
associated with diagnosis and/or prognosis of both primary and
metastatic cancers, along with an appraisal of the translational
implications of this field.
PROSTATE CANCER
Prostate cancer (PC) was the first cancer type to be used
as a disease model for the establishment of circulating miR-
NAs’ potential as blood-based biomarkers. The pioneer work by
Mitchell and colleagues have provided very important insights
and laid the foundation for future investigations on circulat-
ing miRNAs and cancers. This study demonstrated that the
tumor-derived miRNAs from the donor could reach the cir-
culation of the recipient PC xenograft mouse, and could be
subsequently measured in the recipients’ plasma. Additionally,
Mitchell et al. also investigated a few miRNA candidates which
were chosen based on their expression in human prostate spec-
imens and absence in plasma of healthy controls. This investi-
gation performed with serum of metastatic PC (mPC) patients
and healthy control individuals found increased levels of miR-
141, a miRNA involved in epithelial-mesenchymal transition,
in the mPC group (Mitchell et al., 2008). In another study,
pre-selected oncogenic miR-26a, miR-195, and let-7i were first
confirmed to be upregulated in tissue, and then found to be
significantly elevated in serum of PC patients compared to those
with benign prostate hyperplasia (BPH). However, this study
was not able to reproduce the significant difference in miR-141,
and claimed that the miR-141 levels were too low for reliable
testing (Mahn et al., 2011). To achieve the same end-result of
identifying miRNAs that could discriminate PC from BPH and
healthy controls, global miRNAs levels were screened for and
top hits validated. A five miRNA panel consisting of let-7c,
let-7e, miR-30c, miR-622, and miR-1285 was proposed (Chen
et al., 2012a,b). The miRNAs described in the above studies,
due to their ability to discriminate PC from even BPH, are
ideal candidates for early detection of PC, especially those at
high-risk.
Apart from detection, circulating miRNAs have also been con-
nected to prognosis of PC. miR-141, miR-200b, and miR-375
were the first miRNAs identified in this context due to cor-
relations to Gleason score and lymph node affliction (Brase
et al., 2011). The prognostic promise of miR-141 and miR-
375 has been confirmed by two separate studies, in which their
amounts were found to increase from low-risk through high-
risk localized disease toward metastatic cancer (Bryant et al.,
2012; Nguyen et al., 2012). Circulating miRNAs have also been
found to be linked to various PC risk scores such as tumor stage,
CAPRA (Cancer of the Prostate Risk Assessment) and D’Amico
scores (miR-20a, miR-21, miR-145, and miR-221) (Shen et al.,
2012) or have predictive abilities similar to that of circulat-
ing tumour cell (CTC) counts, PSA, and lactate dehydrogenase
(LDH) levels of PC patients (miR-21, miR-141) (Gonzales et al.,
2011).
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Table 1 | Circulating miRNAs reprted to be a biomarker for prostate cancer.
miRNA Sample type Type of biomarker miRNA levels and clinical significance References
let-7c Plasma Diagnostic Decreased in PC compared to BPH and healthy controls Chen et al., 2012a,b
let-7e Plasma Diagnostic Decreased in PC compared to BPH and healthy controls Chen et al., 2012a,b
let-7i Serum Diagnostic Increased in mPC compared to BPH; correlated to Gleason score; Mahn et al., 2011
miR-20a Plasma Prognostic Correlated to rumor stage and D’Amico scores Shen et al., 2012
miR-21 Serum Predictive Increased in HRPC, especially in those resistant to docetaxel-based
chemotherapy
Zhang et al., 2011
miR-21 Plasma Prognostic Correlated to CAPRA scores and D’Amico scores Shen et al., 2012
miR-26a Serum Diagnostic Increased in mPC compared to BPH; decreased in post-operative
samples
Mahn et al., 2011
miR-30c Plasma Diagnostic Decreased in PC compared to BPH and healthy controls Chen et al., 2012a,b
miR-141 Serum Diagnostic Increased in mPC; correlate to PSA levels Mitchell et al., 2008
miR-141 Serum Diagnostic and prognostic Increased in mPC compared to localized PC; correlation to Gleason
score and lymph node status
Brase et al., 2011
miR-141 Plasma Prognostic Correlation to CTC counts, PSA and LDH Gonzales et al., 2011
miR-141 Serum Diagnostic and prognostic Increased in CRPC compared to localized PC Nguyen et al., 2012
miR-145 Plasma Prognostic Correlated to D’Amico scores Shen et al., 2012
miR-195 Serum Diagnostic Increased in mPC compared to BPH; correlated to Gleason score;
decrease in post-operative samples
Mahn et al., 2011
miR-221 Plasma Prognostic Correlated to D’Amico scores Shen et al., 2012
miR-375 Serum Diagnostic and prognostic Increased in mPC compared to localized PC; correlation to Gleason
score and lymph node status
Brase et al., 2011
miR-375 Serum Diagnostic and prognostic Increased in CRPC compared to localized PC Nguyen et al., 2012
miR-378* Serum Diagnostic and prognostic Increased in CRPC compared to localized PC Nguyen et al., 2012
miR-409-3p Serum Diagnostic and prognostic Decreased in CRPC compared to localized PC Nguyen et al., 2012
miR-622 Plasma Diagnostic Increased in PC compared to BPH and healthy controls Chen et al., 2012a,b
miR-1285 Plasma Diagnostic Increased in PC compared to BPH and healthy controls Chen et al., 2012a,b
Abbreviations: BPH, benign prostatic hyperplasia; CTC, circulating tumour cells; HRPC, hormone-refractory prostate cancer; LDH, lactose dehydrogenase; PC,
prostate cancer; PSA, prostate specific antigen; mPC, metastatic prostate cancer.
BREAST CANCER
Currently, there are no early detection markers for primary breast
cancer (PBC) in routine clinical use. Zhu and colleagues per-
formed the first study to understand the association between
serum miR-16, miR-145, miR-155 levels, and breast cancer risk,
and found a correlation of miR-155 to progesterone receptor sta-
tus (Zhu et al., 2009). In one of our studies, which was the first
investigation based on genome-wide approach in PBC,miR-148b,
miR-376c, miR-409-3p, and miR-801 were identified as poten-
tial early stage breast cancer biomarkers in plasma. Interestingly,
miR-148b, miR-376c, and miR-409-3p were present at lower lev-
els in malignant tissue compared to benign breast tissue, whereas
no difference could be detected in miR-801 (Cuk et al., 2013).
An alternate approach of identifying circulating miRNAs capable
of early detection, combed for miRNAs commonly deregulated
in tissue and plasma. This led to the identification of decreased
miR-145 and increased miR-451 levels in plasma of breast cancer
patients in relation to controls, and their plasma levels reflected
those of tissue (Ng et al., 2013). Contrarily, miR-145 was reported
to be upregulated in serum of PBC in another study, which
could be due to the analysis of different sample types by the two
studies (Mar-Aguilar et al., 2013). Recently, analysing circulation
miRNAs that are known to be aberrantly expressed in breast
tissue or have functional role in tumorigenesis has led to the
addition of miR-21 and miR-92a (Si et al., 2013), miR-10b, miR-
125b, miR-155, miR-191, andmiR-382 (Mar-Aguilar et al., 2013),
and miR-30a (Zeng et al., 2013) to this growing list of miR-
NAs for early detection of PBC. Interestingly, while exploring
the difference in plasma miRNA levels between two distinct eth-
nic groups (Caucasian and African-American), different miRNAs
were found to be deregulated in the Caucasian American and
the African-American patients in comparison to their ethnically
matched controls, with an overlap of only two miRNAs (miR-
181a and miR-1304) between them, thus showing that circulating
miRNA profile could depend on ethnicity to some degree (Zhao
et al., 2010).
With respect to the metastatic setting, many reports outline
the identification of circulating miRNAs which have the abil-
ity to discriminate metastatic breast cancer (MBC) from PBC
and/or controls. One such study focusing on both PBC and
MBC uncovered a significant difference in serum total RNA
and miR-155 between PBC and healthy controls, while miR-10b,
miR-34a, and miR-155 correlated with overt metastasis (Roth
et al., 2010). In contrast to this candidate gene-approach, van
Schooneveld et al. found miR-215, miR-299-5p, and miR-411 to
be increased in tissue and also in serum of patients with MBC
compared to healthy individuals by Taqman low density array
cards (van Schooneveld et al., 2012). In a genome-wide array
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Table 2 | Circulating miRNAs reprted to be a biomarker for breast cancer.
miRNA Sample type Type of biomarker miRNA levels and clinical significance References
miR-10b Serum Diagnostic and prognostic Increased in MBC compared to PBC and controls Roth et al., 2010
miR-10b Plasma Prognostic Increased in MBC Chen et al., 2012a,b
miR-10b Serum Diagnostic Increased in PBC Mar-Aguilar et al., 2013
miR-21 Serum Diagnostic Increased in PBC; correlated to tumour size and lymph node
status
Si et al., 2013
miR-21 Serum Diagnostic Increased in PBC Mar-Aguilar et al., 2013
miR-30a Plasma Diagnostic Decreased in PBC; correlated to receptor status Zeng et al., 2013
miR-34a Serum Diagnostic and prognostic Increased in MBC compared to PBC and controls Roth et al., 2010
miR-92a Serum Diagnostic Decreased in PBC; correlated to tumour size and lymph node
status
Si et al., 2013
miR-125b Serum Predictive Increased in patients not responding neoadjuvant chemotherapy Wang et al., 2012a,b,c
miR-125b Serum Diagnostic Increased in PBC Mar-Aguilar et al., 2013
miR-141 Plasma Diagnostic and prognostic Increased in MBC; correlation to CTC status Madhavan et al., 2012
miR-145 Serum Diagnostic Increased in PBC Mar-Aguilar et al., 2013
miR-145 Plasma Diagnostic Decreased in PBC Ng et al., 2013
miR-148b Plasma Diagnostic Increased Cuk et al., 2013
miR-155 Serum Diagnostic Correlation to progesterone receptor status Zhu et al., 2009
miR-155 Serum Diagnostic and prognostic Increased in PBC and MBC compared to controls; increased in
PBC compared to MBC
Roth et al., 2010
miR-155 Serum Diagnostic and predictive Increased in PBC; decrease after surgery and chemotherapy Sun et al., 2012
miR-155 Serum Diagnostic Increased in PBC Mar-Aguilar et al., 2013
miR-191 Serum Diagnostic Increased in PBC Mar-Aguilar et al., 2013
miR-200a Plasma Diagnostic and prognostic Increased in MBC; correlation to CTC status Madhavan et al., 2012
miR-200b Plasma Diagnostic and prognostic Increased in MBC; correlation to CTC status Madhavan et al., 2012
miR-200c Plasma Diagnostic and prognostic Increased in MBC; correlation to CTC status Madhavan et al., 2012
miR-203 Plasma Diagnostic and prognostic Increased in MBC; correlation to CTC status Madhavan et al., 2012
miR-210 Plasma Diagnostic and prognostic Increased in MBC; correlation to CTC status Madhavan et al., 2012
miR-215 Serum Diagnostic Increased in MBC van Schooneveld et al., 2012
miR-299-5p Serum Diagnostic Increased in MBC van Schooneveld et al., 2012
miR-373 Plasma Prognostic Increased in MBC Chen et al., 2012a,b
miR-375 Plasma Diagnostic and prognostic Increased in MBC; correlation to CTC status Madhavan et al., 2012
miR-376c Plasma Diagnostic Increased Cuk et al., 2013
miR-382 Serum Diagnostic Increased in PBC Mar-Aguilar et al., 2013
miR-409-3p Plasma Diagnostic Increased Cuk et al., 2013
miR-411 Serum Diagnostic Increased in MBC van Schooneveld et al., 2012
miR-451 Plasma Diagnostic Increased in PBC Ng et al., 2013
miR-768-3p Plasma Diagnostic Decreased in MBC Madhavan et al., 2012
miR-801 Plasma Diagnostic Increased Cuk et al., 2013
miR-801 Plasma Diagnostic and prognostic Increased in MBC; correlation to CTC status Madhavan et al., 2012
miRNA levels denoted as increased or decreased in cancer cases in comparison to controls unless stated otherwise. Abbreviations: CTC, circulating tumour cells;
PBC, primary breast cancer; MBC, metastatic breast cancer.
based approach, focusing not only on the identification of miR-
NAs for detection of MBC, but also those which could serve as
prognostic markers, we investigated plasma from patients and
controls, and correlated them to CTC status. We detected nine
miRNAs (miR-141, miR-200a, miR-200b, miR-200c, miR-203,
miR-210, miR-375, andmiR-801) which were able to discriminate
between MBC patients based on the presence or absence of CTCs,
as well as MBC patients from healthy individuals. Combinations
of these circulating miRNAs or even miR-200b alone were a bet-
ter marker of progression-free survival and overall survival (OS)
than CTC status, which is an FDA-approved prognostic marker
for MBC (Madhavan et al., 2012). Another recent study inter-
rogated plasma miR-10b and miR-373 levels, which are known
mediators of metastasis in breast cancer, wherein they uncov-
ered association of these miRNAs with lymph node metastasis,
thereby showing potential as prognostic biomarkers (Chen et al.,
2012a,b).
Apart from detection and disease prognosis, circulating miR-
NAs have also been associated with response to breast can-
cer treatment and thus possess predictive capabilities. Serum
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Table 3 | Circulating miRNAs reprted to be a biomarker for lung cancer.
miRNA Sample
type
Type of biomarker miRNA levels and clinical significance References
let-7a Plasma and
serum
Diagnostic Increased; differences between distinct ethnic groups Heegaard et al., 2012
miR-1 Serum Prognostic Decreased levels correlated to poorer OS Hu et al., 2010
miR-15b Plasma Prognostic Decreased in patients with poor outcome Boeri et al., 2011
miR-16 Plasma Prognostic Decreased in aggressive disease Boeri et al., 2011
miR-16 Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miR-17 Plasma Diagnostic and
prognostic
Increased; decreased in patients with poor outcome Boeri et al., 2011
miR-17-5p Plasma and
serum
Diagnostic Increased; differences between distinct ethnic groups Heegaard et al., 2012
miR-19b Plasma Diagnostic Increased Boeri et al., 2011
miR-21 Plasma Prognostic Increased Boeri et al., 2011
miR-21 Plasma Diagnostic Increased Shen et al., 2011
miR-21 Plasma Diagnostic and predictive Increased; predictive for platinum-base chemotherapy. Wei et al., 2011
miR-21 Serum Diagnostic and
prognostic
Increased; decrease in post-operative samples Le et al., 2012
miR-21 Serum Diagnostic and
prognostic
Increased; associated with more advanced stages;
correlated with OS
Liu et al., 2012a,b
miR-21 Plasma Diagnostic Increased in cases compared to healthy smokers Tang et al., 2013
miR-24 Serum Diagnostic and
prognostic
Decrease in post-operative samples Le et al., 2012
miR-25 Serum Diagnostic Increased Chen et al., 2008
miR-27a Plasma and
serum
Diagnostic Increased; differences between distinct ethnic groups Heegaard et al., 2012
miR-28-3p Plasma Diagnostic and
prognostic
Increased; increased in asymptomatic samples compared
to controls too; increased in aggressive disease and
decreased in patients with poor outcome
Boeri et al., 2011
miR-29c Plasma and
serum
Diagnostic Decreased; differences between distinct ethnic groups Heegaard et al., 2012
miR-30c Plasma Diagnostic Increased; increased in asymptomatic samples compared
to controls too
Boeri et al., 2011
miR-30d Serum Prognostic Increased levels correlated to poorer OS Hu et al., 2010
miR-30d Serum Diagnostic Increased Le et al., 2012
miR-92a Plasma Diagnostic Increased; increased in asymptomatic samples compared
to controls too
Boeri et al., 2011
miR-106a Plasma Diagnostic and
prognostic
Increased; increased in aggressive disease and decreased
in patients with poor outcome
Boeri et al., 2011
miR-106a Plasma and
serum
Diagnostic Increased; differences between distinct ethnic groups Heegaard et al., 2012
miR-126 Plasma Prognostic Decreased in patients with poor outcome Boeri et al., 2011
miR-126 Plasma Diagnostic Decreased Shen et al., 2011
miR-140-5p Plasma Diagnostic and
prognostic
Increased; increased in asymptomatic samples compared
to controls too; increased in aggressive disease
Boeri et al., 2011
miR-141 Serum Diagnostic Decreased Liu et al., 2012a,b
miR-142-3p Plasma Prognostic Decreased in patients with poor outcome Boeri et al., 2011
miR-145 Plasma Diagnostic Decreased in cases compared to healthy smokers Tang et al., 2013
miR-146b Plasma and
serum
Diagnostic Increased; differences between distinct ethnic groups Heegaard et al., 2012
miR-148a Plasma Prognostic Decreased in patients with poor outcome Boeri et al., 2011
miR-155 Plasma Diagnostic, prognostic
and predictive
Increased in cases and further increased in patients with
metastasis; decreased in patients responding to therapy
Zheng et al., 2011
(Continued)
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Table 3 | Continued
miRNA Sample
type
Type of biomarker miRNA levels and clinical significance References
miR-155 Plasma and
serum
Diagnostic Increased; differences between distinct ethnic groups Heegaard et al., 2012
miR-155 Plasma Diagnostic Increased in cases compared to healthy smokers Tang et al., 2013
miR-182 Plasma Diagnostic Increased in cases and further increased in patients with
metastasis; decreased in patients responding to therapy
Zheng et al., 2011
miR-182 Plasma Diagnostic Increased Shen et al., 2011
miR-197 Plasma Prognostic Increased in aggressive disease Boeri et al., 2011
miR-197 Plasma Diagnostic, prognostic,
and predictive
Increased in cases and further increased in patients with
metastasis; decreased in patients responding to therapy
Zheng et al., 2011
miR-200c Serum Diagnostic Decreased Liu et al., 2012a,b
miR-205 Serum Diagnostic Increased Le et al., 2012
miR-210 Plasma Diagnostic Increased Shen et al., 2011
miR-221 Plasma Prognostic Increased in aggressive disease; decreased in patients with
poor outcome
Boeri et al., 2011
miR-221 Plasma and
serum
Diagnostic Increased; differences between distinct ethnic groups Heegaard et al., 2012
miR-223 Serum Diagnostic Increased Chen et al., 2008
miR-451 Plasma Diagnostic and
prognostic
Increased; increased in asymptomatic samples compared
to controls too
Boeri et al., 2011
miR-452* Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miR-486 Serum Prognostic Increased levels correlated to poorer OS Hu et al., 2010
miR-486-5p Plasma Prognostic Increased in aggressive disease Boeri et al., 2011
miR-486-5p Plasma Diagnostic Decreased Shen et al., 2011
miR-499 Serum Prognostic Decreased levels correlated to poorer OS Hu et al., 2010
miR-518a-5p Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miR-574-5p Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miR-574-5p Serum Diagnostic Increased Foss et al., 2011
miR-593* Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miR-660 Plasma Diagnostic and
prognostic
Increased; increased in asymptomatic samples compared
to controls too
Boeri et al., 2011
miR-663 Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miR-718 Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miR-1228* Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miR-1254 Serum Diagnostic Increased Foss et al., 2011
miR-1972 Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miR-2114* Serum Diagnostic Decreased in pre- (asymptomatic) and post-diagnostic
samples
Keller et al., 2011
miRNA levels denoted as increased or decreased in cancer cases in comparison to controls unless stated otherwise. Note: The 30 miRNA signature described by
Bianchi et al. (2011) has not been included here. Please refer to the original paper. Abbreviations: OS, overall survival.
miR-125b (Wang et al., 2012a,b,c) and miR-155 (Sun et al., 2012)
have been linked to chemotherapy response. Furthermore, miR-
30a and miR-155 have been demonstrated as more accurate than
the predictive markers CEA and CA 15-3, which are currently in
use for monitoring treatment inMBC (Harris et al., 2007; Uehara
et al., 2008; Sun et al., 2012; Zeng et al., 2013).
LUNG CANCER
Lung cancer has been extensively studied with respect to its cir-
culating miRNA profile and majority of studies reviewed here
have concentrated on non-small-cell lung cancer (NSCLC), the
more common type. The first study to systematically characterize
miRNAs in serum by Solexa sequencing identified sixty three
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Table 4 | Circulating miRNAs reprted to be a biomarker for colorectal cancer.
miRNA Sample type Type of biomarker miRNA levels and clinical significance References
miR-15b Plasma Diagnostic Increased Giraldez et al., 2012
miR-17-3p Plasma Diagnostic Increase; decrease in post-operative samples Ng et al., 2009
miR-18a Plasma Diagnostic Increased in CRC and advanced adenomas compared to
controls
Giraldez et al., 2012
miR-19a Plasma Diagnostic Increased Giraldez et al., 2012
miR-21 Plasma Diagnostic Increased Kanaan et al., 2012
miR-29a Plasma Diagnostic Increased in CRC and advanced adenomas compared to
controls
Huang et al., 2010
miR-29a Plasma Diagnostic Increased Giraldez et al., 2012
miR-29a Serum Diagnostic and prognostic Increased in crc with liver metastasis compared to
non-metastatic CRC
Wang and Gu, 2012
miR-92 Plasma Diagnostic Increase; decrease in post-operative samples; can
differentiate CRC from gastric cancer IBD and controls
Ng et al., 2009
miR-92a Plasma Diagnostic Increased in CRC and advanced adenomas compared to
controls
Huang et al., 2010
miR-141 Plasma Prognostic Increased; correlated to OS Cheng et al., 2011
miR-221 Plasma Diagnostic and prognostic Increased; correlated to OS and p53 score Pu et al., 2010
miR-335 Plasma Diagnostic Increased Giraldez et al., 2012
miR-601 Plasma Diagnostic Decreased in CRC and advanced adenomas compared to
controls
Wang et al., 2012a,b,c
miR-760 Plasma Diagnostic Decreased in CRC and advanced adenomas compared to
controls
Wang et al., 2012a,b,c
miR-1246 Plasma and serum Diagnostic A pseudo-microRNA representing an RNU2-1 fragment Baraniskin et al., 2013
miRNA levels denoted as increased or decreased in cancer cases in comparison to controls unless stated otherwise. Abbreviations: CRC, colorectal cancer; IBD,
inflammatory bowel disease; OS, overall survival.
circulating miRNAs in NSCLC patients that were not detected
in control samples, and ultimately miR-25 and miR-223 were
highlighted as the most promising diagnostic markers (Chen
et al., 2008). Another study adopting a global miRNA screening
recommended miR-574-5p and miR-1254 as detection markers
(Foss et al., 2011). As opposed to this global approach, Shen
et al. verified miRNAs in plasma of NSCLC patients and con-
trols, which were previously reported as differentially expressed
in sputum. A panel of four miRNAs (miR-21, miR-126, miR-486-
5p, and miR-210) was declared as having the highest predictive
power for all stages of NSCLC, with a higher diagnostic sensitiv-
ity for more advanced stages (Shen et al., 2011). The diagnostic
value of miR-21, once again, along with miR-145 and miR-
155 was confirmed by validating their significant deregulation
between malignant NSCLC and healthy smokers (Tang et al.,
2013).
While the above studies aimed to identify circulating miR-
NAs that could identify NSCLC patients, Boeri et al. and Bianchi
et al. attempted to distinguish miRNAs that could also be use-
ful in the diagnosis of asymptomatic patients in plasma and
serum, respectively (Bianchi et al., 2011; Boeri et al., 2011). The
first study conducted a comprehensive analysis, and put forth
a miRNA signature in plasma capable of detecting lung cancer
in asymptomatic patients before clinical presentation of disease.
miR-28-3p, miR-30c, miR-92a, miR-140-5p, miR-451, and miR-
660 were the most robust miRNAs to predict the development
of lung cancer, as they were deregulated in samples collected
from patients even 1–2 years prior to diagnosis when compared
to control individuals. In case of samples collected at the time-
point of diagnosis, miR-17, miR-19b, miR-92a, miR-106a, and
miR-660 were also found to be informative (Boeri et al., 2011).
Bianchi and co-workers analysed serum samples from asymp-
tomatic NSCLC patients and healthy smokers, and identified a
signature of 34 miRNAs with the capacity to (1) identify early
stage NSCLC patients and, (2) discriminate between benign and
malignant lesions, thus detecting the onset of a malignant dis-
ease (Bianchi et al., 2011). A retrospective study, which profiled
serum miRNAs in pre- and post-diagnostic NSCLC samples, and
compared them to normal controls validated miR-16, miR-452∗,
miR-518a-5p, miR-574-5p, miR-593∗, miR-663, miR-718, miR-
1228∗, miR-1972, and miR-2114∗ to be significantly deregulated
in both categories of cases, thus making them ideal markers for
early detection (Keller et al., 2011). These studies concur on their
inference that dramatic changes in circulating miRNA profile
occur at time points closer to cancer diagnosis, thus supporting
the idea thatmiRNAsmay predict cancer development years prior
to clinically symptomatic disease.
With a very poor 5-year survival rate in lung cancer patients,
markers to assess prognosis or predict therapy response are
equally important. When pre-diagnostic samples of patients with
an unfavorable clinical outcome were investigated, two sets of
miRNAs were developed to help identify patients at risk for
aggressive disease and prognosticate outcome (Boeri et al., 2011).
By genome-wide sequencing of serum of patients with longer
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Table 5 | Circulating miRNAs reprted to be a biomarker for gastric cancer.
miRNA Sample type Type of biomarker miRNA levels and clinical significance References
let-7a Plasma Diagnostic Decreased Tsujiura et al., 2010
miR-1 Serum Diagnostic Increased; correlated to tumour stage Liu et al., 2011
miR-17-5p Plasma Diagnostic Increased Tsujiura et al., 2010
miR-17-5p Plasma Diagnostic and prognostic Increased; correlated to tnm staging, a poor OS Wang et al., 2012a,b,c
miR-20a Serum Diagnostic Increased; correlated to tumour stage Liu et al., 2011
miR-20a Plasma Diagnostic and prognostic Increased; correlated to tnm staging, a poor OS;
independent risk predictor for prognosis
Wang et al., 2012a,b,c
miR-20a Plasma Diagnostic Increased Cai et al., 2013
miR-21 Plasma Diagnostic Increased; decrease in post-operative samples Tsujiura et al., 2010
miR-21 Plasma Diagnostic Increased Li et al., 2012a,b
miR-27a Serum Diagnostic Increased; correlated to tumour stage Liu et al., 2011
miR-34 Serum Diagnostic Increased; correlated to tumour stage Liu et al., 2011
miR-106a Plasma Diagnostic Increased; decrease in post-operative samples Tsujiura et al., 2010
miR-106b Plasma Diagnostic Increased Tsujiura et al., 2010
miR-106b Plasma Diagnostic Increased Cai et al., 2013
miR-151-5p Plasma Diagnostic Increased; decrease in post-operative samples Li et al., 2012a,b
miR-187* Serum Diagnostic Increased Liu et al., 2012a,b
miR-199a-3p Plasma Diagnostic Increased; decrease in post-operative samples; associated
with lymph node metastasis and tnm staging
Li et al., 2012a,b
miR-218 Plasma Diagnostic Decreased Li et al., 2012a,b
miR-221 Serum Diagnostic Increased in cancer and dysplasia compared to controls;
correlated with poor differentiation of cancer; showed
retrospective correlation in pre-diagnostic samples
Song et al., 2012
miR-221 Plasma Diagnostic Increased Cai et al., 2013
miR-223 Plasma Diagnostic Increased; associated with helicobacter pylori infection Li et al., 2012a,b
miR-371-5p Serum Diagnostic Increased Liu et al., 2012a,b
miR-376c Serum Diagnostic Increased; correlated with poor differentiation of cancer;
showed retrospective correlation in pre-diagnostic samples
Song et al., 2012
miR-378 Serum Diagnostic Increased Liu et al., 2012a,b
miR-423-5p Serum Diagnostic Increased; correlated to tumour stage Liu et al., 2011
miR-451 Plasma Diagnostic Increased; decrease in post-operative samples Konishi et al., 2012
miR-486 Plasma Diagnostic Increased; decrease in post-operative samples Konishi et al., 2012
miR-744 Serum Diagnostic Increased; showed retrospective correlation in
pre-diagnostic samples
Song et al., 2012
miRNA levels denoted as increased or decreased in cancer cases in comparison to controls unless stated otherwise. Abbreviations: OS, overall survival.
and those with shorter survival, Hu et al. determined the levels
of serum miR-1, miR-30d, miR-486, and miR-499 to be linked
to survival in NSCLC patients. Specifically, patients having two
or more of these “high-risk” miRNAs deregulated were found
to have a higher probability of shortened survival compared to
patients with none or just one deregulated miRNA. The four-
miRNA signature was propounded as an independent predictor
of OS (Hu et al., 2010). Although in this study miR-21 was one
of the top three hits of sequencing, it could not be successfully
validated in a larger cohort. Nevertheless, circulating miR-21 has
been repeatedly reported as being deregulated in lung cancer
patients and possessing prognostic value, and has specifically been
associated with (1) lymph node metastasis and advanced cancer
stage, (2) patient survival prognosis, (3) sensitivity to platinum-
based chemotherapy, and (4) post-operative disease monitoring
(Wei et al., 2011; Le et al., 2012; Liu et al., 2012a,b). A recent study
found miR-142-3p to be associated with a high risk of recurrence
in early-stage lung adenocarcinoma patients, and thus proposed
it as a putative serum marker for risk assessment (Kaduthanam
et al., 2013). With respect to the predictive value, plasma lev-
els of miR-155, miR-182, and miR-197 which were shown to be
increased in patients, and especially those with metastasis, exhib-
ited a significant decrease in lung cancer patients who respond to
chemotherapy (Zheng et al., 2011).
Heegaard et al., in addition to identifying circulating miRNAs
for diagnostic purposes in NSCLC, compared plasma and serum
miRNA profile, and miRNA profile of different ethnic groups.
Notably, the miRNA levels in paired plasma and serum from the
early stage NSCLC patients showed no significant correlation.
Reduced levels of miR-17-5p, miR-27a, miR-106a, miR-146b,
miR-155, miR-221, and let-7a, and increased levels of miR-29c
were detected only in the serum of NSCLC patients and not in
plasma (Heegaard et al., 2012). Analogous to the findings in a
breast cancer study, the miRNA profiles also displayed differences
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Table 6 | Circulating miRNAs reprted to be a biomarker for hematological cancers.
miRNA Cancer Sample type Type of biomarker miRNA levels and clinical
significance
References
let-7b AML Plasma Diagnostic Increased Fayyad-Kazan et al., 2013
let-7d AML Plasma Diagnostic Decreased Fayyad-Kazan et al., 2013
miR-10a-5p AML Serum Diagnostic Increased Zhi et al., 2013
miR-15a de novo DLBCL Serum Diagnostic Increased Fang et al., 2012
miR-16-1 de novo DLBCL Serum Diagnostic Increased Fang et al., 2012
miR-21 de novo DLBCL Serum Diagnostic Increased Lawrie et al., 2008
miR-29c de novo DLBCL Serum Diagnostic Increased Fang et al., 2012
miR-34a de novo DLBCL Serum Diagnostic Increased Fang et al., 2012
miR-92a AML Plasma Diagnostic Decreased Tanaka et al., 2009
miR-92a NHL Plasma Diagnostic and predictive Decreased; further decreased in
patients with decreased RFS
Ohyashiki et al., 2011
miR-93-5p AML Serum Diagnostic Increased Zhi et al., 2013
miR-129-5p AML Serum Diagnostic Increased Zhi et al., 2013
miR-150 AML Plasma Diagnostic and prognostic Decreased; increased in cases with
CR compared to those without CR
Fayyad-Kazan et al., 2013
miR-155 de novo DLBCL Serum Diagnostic Increased Lawrie et al., 2008
miR-155 de novo DLBCL Serum Diagnostic Increased Fang et al., 2012
miR-155-5p de novo DLBCL Serum Diagnostic Increased Zhi et al., 2013
miR-181b-5p de novo DLBCL Serum Diagnostic and prognostic Increased; correlates to OS Zhi et al., 2013
miR-210 de novo DLBCL Serum Diagnostic Increased; high levels correlate with
improved RFS
Lawrie et al., 2008
miR-221 de novo DLBCL Plasma Diagnostic and prognostic Increased; correlates to OS Guo et al., 2010
miR-320d de novo DLBCL Serum Diagnostic Increased Zhi et al., 2013
miR-339 de novo DLBCL Plasma Diagnostic Decreased Fayyad-Kazan et al., 2013
miR-342 de novo DLBCL Plasma Diagnostic and prognostic Decreased; increased in cases with
CR compared to those without CR
Fayyad-Kazan et al., 2013
miR-523 AML Plasma Diagnostic Increased Fayyad-Kazan et al., 2013
miRNA levels denoted as increased or decreased in cancer cases in comparison to controls unless stated otherwise. Abbreviations: AML, acute myeloid leukemia;
CR, complete remission; DLBCL, diffuse large B cell lymphoma; NHL, non-Hodgkin’s lymphoma; OS, overall survival; RFS, relapse-free survival.
between the African American and European American ethnic
groups (Zhao et al., 2010; Heegaard et al., 2012).
COLORECTAL CANCER
In colorectal cancer (CRC) many studies have evaluated the fea-
sibility of circulating miRNAs for detecting early stage cancer
and also as prognostic/predictive marker (Pfütze et al., 2013). Ng
et al. achieved this by profiling miRNAs in tissue and plasma,
and short-listing miRNAs that were differentially expressed in
both. Ultimately, miR-17-3p and miR-92, both belonging to the
same miRNA gene cluster and classified as oncogenic, were vali-
dated as elevated in CRC plasma and CRC tissue, in comparison
to their normal counterparts. The two miRNAs were also pro-
posed as responsive to surgery as lower levels were detected in
post-operative plasma compared to pre-operative plasma, thus
expanding their role as biomarkers. Interestingly, miR-92 alone
had the potential to discriminate CRC samples from other dis-
eases, such as gastric cancer (GC) and inflammatory bowel disease
samples, apart from controls (Ng et al., 2009). The diagnostic
potential of miR-92a was further confirmed by another study
in plasma, which in addition also identified miR-29a as being
increased in CRC, and similar to the previous study the miRNAs
showed reduction following surgery. However, this study was not
able to validate miR-17-3p as it could not be measured due to
very low levels in plasma. miR-29a and miR-92a could also differ-
entiate adenomas (pre-malignant lesions) from control samples,
however their sensitivity to differentiate adenomas from carcino-
mas was not mentioned, which might influence their diagnostic
utility (Huang et al., 2010). By miRNA profiling and subsequent
validation, miR-601 and miR-760 were also suggested as poten-
tial diagnostic biomarkers of adenomas and CRC by the same
group. Combining miR-29a, miR-92a, and miR-760, the detec-
tion sensitivity of early stages of CRC was further improved,
especially when complemented with CEA (Wang et al., 2012a,b,c).
miR-29a amounts in serum has also been reported to discrim-
inate metastatic and non-metastatic CRC patients, specifically
liver metastasis (Wang and Gu, 2012). Another study which
undertook a genome-wide miRNA profiling of plasma, iden-
tified miR-15b, miR-19a, miR-19b, miR-29a, and miR-335 as
being able to differentiate CRC patients from healthy individu-
als, while miR-18a could do so also between advanced adenomas
and healthy individuals (Giraldez et al., 2012). miR-21 was iden-
tified as an early detection marker, but here, rather than profiling
plasma, the strategy followed was to profile CRC and normal
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tissue, and validate the top hits from this discovery round in
plasma (Kanaan et al., 2012). miR-1246, in spite of being desig-
nated as a pseudo-miRNA, was discerned as a diagnostic marker
for pancreatic ductal adenocarcinoma and CRC in serum and
plasma, and predictive for early therapy response prediction of
chemo- and radiation therapy due to its decline following sur-
gical resection. The measured signal, which was discriminating
cancer and control samples, was proposed to have come from the
U2 small nuclear RNA (snRNA) fragment RNU2-1f (Baraniskin
et al., 2013).
Although many studies have outlined the diagnostic poten-
tial of circulating miRNAs in CRC, not many have explored their
prognostic potential. One such study measured oncogenic miR-
NAs and identified plasmamiR-221 to have prognostic prowess in
addition to being diagnostic for CRC. miR-221 levels significantly
correlated to OS and p53 expression (Pu et al., 2010). The only
other report in this direction showed miR-141 to be highly corre-
lated to cancer stage, complemented CEA in identifying stage IV
CRC, and associated with poorer OS (Cheng et al., 2011).
GASTRIC CANCER
GC has one of the poorest survival rates, which makes the dis-
covery of suitable biomarkers for early detection or prognosis
all the more important (Siegel et al., 2012). Based on previous
findings in GC tissue samples, miR-17-5p, miR-21, miR-106a,
miR-106b, and let-7a were chosen for analysis in plasma sam-
ples. While the first four were demonstrated to be present at
significantly higher levels, let-7a was lower in GC patients than
in healthy individuals. In addition to this, a significant drop in
the levels of miR-21 and miR-106b in post-operative paired sam-
ples, and a concordance between tissue and plasma miRNAs were
also observed. The authors interpreted from these results that the
levels of plasma miRNAs reflected the corresponding expression
level in tumour (Tsujiura et al., 2010). Unlike this study, Liu et al.
carried out a global miRNA screening in GC and healthy con-
trol serum samples, independent of miRNA profile in tissue. A
five miRNA signature in serum was identified to be markedly
upregulated in GC patients, and within GC samples, addition-
ally correlated to tumour stage, thereby an advanced clinical stage.
Its discriminatory power was claimed to be even higher than cur-
rently establishedmarkers, CEA and CA 19-9. This was attributed
to the use of multiple miRNAs which were functionally associ-
ated to various tumorigenic processes (immune response-related:
miR-20a and miR-423-5p; tissue-specific: miR-1; tumour cell
growth/cycle-related: miR-27a and miR-34). This, they claimed,
could prove to be more comprehensive than a conventional single
protein-based biomarker (Liu et al., 2011). Another study using
miRNA profiling of serum uncovered 16 upregulated miRNAs
in the discovery round. These included miR-17, miR-20a, miR-
21, and miR-106a/b among others, which eventually could not
be validated unlike in the previous studies mentioned here. After
validation, miR-221, miR-376c, and miR-744 were delineated as
markers for GC detection, capable of identifying GC even 5 years
prior to clinical diagnosis (Song et al., 2012). By comparing pre-
and post-operative plasma samples, miR-451 and miR-486 (both
lowered in post-operation) were selected as candidates and con-
firmed to be present in higher amounts in GC as opposed to
controls (Konishi et al., 2012). One more study dealing with GC
plasma samples demonstrated miR-21 and miR-223 to be sig-
nificantly higher in GC patients than in healthy controls, while
miR-218 was significantly lower. Interestingly, miR-223 was also
specifically correlated to Helicobacter pylori infection, an etiolog-
ical agent for GC (Li et al., 2012a,b). Other miRNAs proposed as
diagnostic markers for GC include miR-151-5p and miR-199a-
3p (Li et al., 2012a,b), and miR-221 (Cai et al., 2013) which
were identified in plasma. The latter study also re-affirmed the
potential of miR-20a andmiR-106b to differentiate GC from con-
trols (Cai et al., 2013). Of these, miR-199a-3p was also associated
with lymph node metastasis and TNM staging, thus increasing
its diagnostic importance (Li et al., 2012a,b). With respect to
serum, miR-187∗, miR-371-5p, and miR-378 were found to be
significantly elevated in GC patients, with miR-378 being singled
out as the most informative (Liu et al., 2012a,b).
Of the above mentioned miRNAs, miR-17-5p, and miR-21
were tested in an independent study to not only be elevated in
GC, but also significantly correlated to TNM staging, and a poor
OS, and miR-21 alone was defined as an independent prognos-
tic marker (Wang et al., 2012a,b,c). Other than this one report,
not many studies focusing on the prognostic role of circulating
miRNAs in GC have been published.
HAEMATOLOGICAL CANCERS
Although circulating miRNAs from plasma or serum are in close
contact with their cellular counterpart and could easily reflect any
abnormality of blood cells, there has been very little research in
this direction. The first foray into the field of circulating miRNAs
in cancer was with diffuse large B cell lymphoma (DLBCL) where
tumour-associated miR-21, miR-155, and miR-210 were shown
to be significantly higher in the serum of cancer patient serum
than in healthy controls. In addition to its diagnostic proficiency,
miR-21 also showed correlation to relapse-free survival (Lawrie
et al., 2008). miR-15a, miR-16-1, miR-29c, miR-34a, and miR-
155, which are known tumour-associated miRNAs, were later
also defined as early detection markers for DLBCL, with miR-
155 being the only common miRNA in these two studies (Lawrie
et al., 2008; Fang et al., 2012). Since the miR-17-92 polycistronic
miRNA cluster plays a crucial role in lymphomagenesis and
affects neo-angiogenesis, one study explored the diagnostic and
prognostic value of plasmamiR-92a in non-Hodgkin’s lymphoma
(NHL). miR-92a was found to be extremely low in patients, and
additionally evinced a strong correlation to relapse rates among
patients (Ohyashiki et al., 2011). Another study, extrapolating
the functional role of miRNAs in cancer to its diagnostic poten-
tial, screened for miR-221. Based on the hypothesis that miRNAs
functionally involved in resistance to a particular chemotherapeu-
tic drug would harbor information regarding treatment response,
Guo et al. measured miR-221 (increased in adriamycin resistant
cancer cells) in extra-nodal natural killer T-Cell (NK/T-cell) lym-
phoma, which is a very aggressive form with very poor prognosis.
Plasma miR-221 was able to distinguish patients from controls,
and also demonstrated prognostic value by being correlated to OS
(Guo et al., 2010).
Leukemia is another type of hematological cancer where circu-
lating miRNAs have been probed. In addition to NHL, miR-92a
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has also been observed to be decreased in plasma of acute myeloid
leukemia (AML) patients. This study reported the ratio of miR-
92a/miR-638 as having the strongest detection value for AML,
where miR-638 was considered an internal reference gene (Tanaka
et al., 2009). As opposed to this knowledge-based approach, a
recent article outlined the identification of candidate miRNAs
from microarray experiments in plasma. let-7d, miR-150, miR-
339, and miR-342 were identified to be depressed, whilst let-7b,
and miR-523 to be increased in AML patients at diagnosis when
compared to controls. The combination of miR-150 and miR-
342 was found to be the most accurate model for diagnostic
purposes, and their prognostic value was also contemplated due
to their elevation in patients with complete remission (Fayyad-
Kazan et al., 2013). Another study on AML carried out whole
miRNome sequencing to identify candidate miRNAs in serum
differentially regulated from controls, and was able to success-
fully validate six miRNAs; miR-10a-5p, miR-93-5p, miR-129-5p,
miR-155-5p, miR-181b-5p, and miR-320d. More importantly,
miR-181b-5p levels in serum showed significant association with
OS (Zhi et al., 2013).
CONCLUSION AND FUTURE PERSPECTIVES
We have seen a tremendous growth of interest in the area of cir-
culating miRNAs that could be developed as cancer biomarkers.
From the body of work presented here some interesting obser-
vations and interpretations can be made. A few miRNAs seem
to be prevalent and are associated with different cancer, for e.g.,
oncogenic miR-17-92 cluster which shows involvement in both
solid and blood cancers, hence their use as diagnostic markers
could be a double edged sword for example, while they could
cover a broad spectrum of cancers, they would lack specificity.
Circulating miRNAs that can identify cancer development years
prior to disease onset or in asymptomatic individuals, as shown in
lung and GC, could be used for the screening of high-risk groups
(Song et al., 2012). Different approaches have been adopted to
identify these circulating miRNA biomarkers such as genome-
wide profiling, knowledge-based candidate approach, analysing
for those miRNAs known to be deregulated in tissue, etc., with
each approach having its own advantages and disadvantages.
From the conflicting results regarding concordance between miR-
NAs in tumour tissue and those in circulation between studies,
one can infer that the circulating miRNAs have a heteroge-
neous origin, which has also been corroborated by other studies
(Turchinovich et al., 2012). Finally, most studies propose combi-
nation of miRNAs rather than a single miRNA for discriminat-
ing cancer patients from controls, or for determining prognosis
of patients, implying the advantage of using miRNAs involved
in different physio-pathological pathways to obtain a complete
picture.
Crucial to the translational value of any biomarker is its
robustness and reproducibility. As with all upcoming fields, there
are a few technical glitches, such as sample preparation for plasma
or serum and data normalization, that still need to be dealt with.
Establishing a standardized protocol which should be prefer-
ably followed across all studies is very important and desirable.
This would facilitate comparison and (re-)affirmation of results
from different cohorts and enhance detection of only those cir-
culating miRNAs that give us information about the biological
state of samples rather than confounding us with physiological
or systemic differences. Most studies, with very few exceptions,
deal with relatively small sample sizes and lack validation in
independent cohort(s). To achieve true translational relevance
and bring circulating miRNAs into routine diagnostics, we need
to invest in larger study cohorts and reproducibly validate the
results. Nevertheless, all the current data underlines the enor-
mous prospective for circulating miRNAs in the field of cancer as
(1) diagnostic biomarkers for early detection of cancer; (2) prog-
nostic biomarkers helping to predict outcome and (3) predictive
biomarkers which are associated with response or resistance to a
particular therapy option, and thus aid in treatment planning.
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